NCT04524611: Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
- State
- Under way
- Phase
- Phase 3
- People
- 527 taking part
- Started
- 30 Sep 2020
- Primary completion
- Feb 2028
- Arms
- Risankizumab Dose A Followed by Dose B
- Results
- None posted
- 24 Aug 2020: Trial registered
- 30 Sep 2020: Trial started